The most advanced next-generation obesity drugs are retatrutide (a triple agonist with Phase 3 data near 25 to 29 percent weight loss), orforglipron (an oral GLP-1 with published Phase 3 results), and CagriSema (a semaglutide plus amylin combination). None of the investigational ones is FDA approved yet. This guide covers what the current trial data actually shows, which drugs are closest to market, and how they compare to the approved options.
What are the most promising new weight loss drugs?
The strongest pipeline candidates right now are retatrutide, orforglipron, and CagriSema, with survodutide, mazdutide, maridebart cafraglutide, and several others behind them. Retatrutide has produced the highest weight-loss numbers in trials, orforglipron is notable for being an oral pill rather than an injection, and CagriSema pairs an established GLP-1 with an amylin analog.
A reality check before the rankings: pipeline means not yet approved. Trial results are promising but can shift, and a drug that looks strong in Phase 2 sometimes underdelivers in Phase 3, which is exactly what makes head-to-head efficiency comparisons across stages unreliable.
Retatrutide: the triple agonist with the highest trial numbers
Retatrutide, developed by Eli Lilly, activates three receptors: GLP-1, GIP, and glucagon. The glucagon component is thought to add energy expenditure on top of appetite reduction.
The data has matured past the early Phase 2 results. In the Phase 3 TRIUMPH-1 trial at 80 weeks, participants lost roughly 17.6 percent of body weight at 4mg, 23.7 percent at 9mg, and 25.0 percent at 12mg, versus about 3.9 percent on placebo. The TRIUMPH-4 trial in people with obesity and knee osteoarthritis reported about 28.7 percent weight loss at the 12mg dose at 68 weeks. These are among the highest figures reported for any obesity drug. Retatrutide is still investigational and not available by prescription.
Orforglipron: the oral GLP-1
Orforglipron is an oral, non-peptide GLP-1 receptor agonist from Eli Lilly, which is significant because it is a daily pill rather than an injection and does not have the food and water timing restrictions of oral semaglutide tablets.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Phase 3 ATTAIN-1 results have been published. At the highest dose, participants lost an average of about 12.4 percent of body weight at 72 weeks, with a large share reaching at least 10 percent loss. Lilly has indicated it is pursuing global regulatory submissions. The weight loss is more modest than the injectable triple agonists, but the oral route could matter a lot for access and adherence.
CagriSema: semaglutide plus amylin
CagriSema, from Novo Nordisk, combines semaglutide with cagrilintide, an amylin analog, to hit appetite regulation through two pathways. It has been one of the most anticipated combinations.
Be careful with the numbers circulating online. The Phase 3 REDEFINE program reported weight loss that, while substantial, came in below some of the early expectations the market had set. The honest framing is that CagriSema is a strong candidate with meaningful weight loss, not a confirmed leader, and the final positioning depends on full data and labeling.
The rest of the pipeline
| Drug | Mechanism | Route | Status |
|---|---|---|---|
| Retatrutide | GLP-1 / GIP / glucagon triple agonist | Injection | Phase 3 data out; not approved |
| Orforglipron | Oral GLP-1 agonist | Oral pill | Phase 3 published; submission underway |
| CagriSema | Semaglutide + amylin | Injection | Phase 3 reported; not approved |
| Survodutide | GLP-1 / glucagon dual agonist | Injection | Phase 3 ongoing; liver focus |
| Mazdutide | GLP-1 / glucagon dual agonist | Injection | In development |
| Maridebart cafraglutide | GLP-1 / GIP, antibody-based | Injection | Earlier stage; infrequent dosing |
| Danuglipron | Oral GLP-1 agonist | Oral pill | Development setbacks reported |
Treat this as a snapshot. Pipeline status changes, and being in trials is not the same as being available.
How do the new drugs compare to semaglutide and tirzepatide?
Approved semaglutide produces roughly 15 percent average weight loss in trials, and tirzepatide produces more, in the low-to-mid 20 percent range at higher doses. The investigational triple agonist retatrutide has reported higher numbers still, but it is not approved, while oral orforglipron has come in lower than the injectables but offers pill convenience. The approved drugs are the ones you can actually get prescribed today.
Can I get these new weight loss drugs now?
Mostly no. Retatrutide, orforglipron, CagriSema, survodutide, and the rest are investigational and not available by prescription outside of trials. The options you can access today are the approved and compounded forms of semaglutide and tirzepatide. FormBlends provides physician-supervised compounded semaglutide and tirzepatide GLP-1 programs. It does not sell retatrutide or any investigational pipeline drug. If you want a treatment you can start now, the approved GLP-1 medications are the realistic path while the pipeline matures.
Frequently asked questions
What is the most effective weight loss drug in development?
Retatrutide has reported the highest trial weight loss, around 25 to 29 percent at higher doses in Phase 3, but it is not approved.
When will retatrutide be available?
It is still investigational. Timing depends on completion of the Phase 3 program and regulatory review.
Is orforglipron a pill?
Yes. It is an oral GLP-1 agonist, which sets it apart from the injectable candidates.
How much weight loss does orforglipron produce?
Phase 3 ATTAIN-1 reported about 12.4 percent at the highest dose at 72 weeks.
Is CagriSema better than tirzepatide?
That is not settled. Phase 3 CagriSema results were strong but came in below some early expectations. Final positioning depends on full data.
Can I buy these drugs online now?
No. The investigational ones are not legally available by prescription. Approved semaglutide and tirzepatide are what you can access.
Which pipeline drug is best for liver disease?
Survodutide is being studied specifically for metabolic liver disease alongside obesity.
Are these new drugs FDA approved?
The pipeline candidates are not yet approved. Semaglutide and tirzepatide already are.
Related guides
- AOD-9604 for Weight Loss Plateau Breaking: Evidence and Guide
- Aod 9604 Peptide Fat Loss Weight Management
- 10 Best Peptides for Weight Loss in 2025: Ranked by Evidence
- Best Weight Loss Injections in 2025: Every Option Ranked
- How To Spot Fake Weight Loss Medications
- Peptides for Weight Loss: Which Ones Work? 2026
Sources
- Eli Lilly, retatrutide TRIUMPH Phase 3 results announcements: https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average
- Eli Lilly, orforglipron ATTAIN-1 Phase 3 results: https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-meaningful-weight
- Jastreboff AM, et al., Retatrutide Phase 2 trial, New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
- WebMD, obesity drug research pipeline overview: https://www.webmd.com/obesity/obesity-drug-research
- Novo Nordisk CagriSema REDEFINE program updates: https://www.novonordisk.com/news-and-media/news-and-ir-materials.html
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →